Studying immune cells after stem cell transplant for blood cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at natural killer (NK) cells, which are part of the immune system, in the blood of people who have had a stem cell transplant for acute leukemia or myelodysplasia. It aims to understand how these cells change after transplant and potentially predict outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have been diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS).
- You are scheduled to receive or have already received a stem cell transplant (also called a bone marrow transplant).
- You may be taking a drug called azacitidine (AZA) after the transplant, but it is not required.
- You cannot join if you are pregnant, breastfeeding, a minor, or under legal guardianship.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how certain proteins in the blood around the time of a stem cell transplant may differ based on your blood disease and the type of donor you have. It aims to help doctors understand how to better support patients during stem cell transplants.
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
This study looks at changes in your immune cells (T cells) in people with acute myeloid leukemia (AML) who are scheduled for a donor stem cell transplant. It may help doctors better understand how the immune system responds during and after transplant.
This study uses blood samples from people with acute myeloid leukemia (AML) and from healthy stem cell donors to learn how to make immune cells better at killing cancer. The goal is to develop a new type of treatment that helps the body's own defenses fight the disease.
This study aims to collect, store, and share data from patients who are receiving standard intensive treatment and a stem cell transplant from either their own cells or a donor. It may help improve how future patients are treated by building a reliable record of outcomes and care patterns.
This study looks at how your body processes medications after a stem cell transplant from a donor. It aims to find the best way to test your genes to improve future treatments.
Hear when a new Leukaemia (Acute Myeloid) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.